Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

A new consensus report on the management of type 1 diabetes in adults was presented recently at the European Association for ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Election Day, or the general election, is Tuesday, Nov. 4. In the general election, voters will consider statewide ...

Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...

AI is revolutionizing how the Department of Homeland Security protects the U.S. via better border and airport security, as examples.

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

EXCLUSIVE: The Express has campaigned for cystic fibrosis sufferers for six years but now a charity is highlighting the CF ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The ...